Lecanemab Sweeps Up Toxic Aβ Protofibrils, Catches Eyes of Trialists
In a comparison with aducanumab and gantenerumab, lecanemab mopped up protofibrils most efficiently; the antibody has been chosen for DIAN-TU and AHEAD 3-45 trials.
ALL NEWS
6514 RESULTS
Sort By:
- Most Recent
- Most Commented
Paper Alert: Massive GWAS Meta-Analysis Published
The huge collaborative effort unearthed 42 new risk loci and confirmed 33 others. The hits reinforce known disease pathways and predict progression.
Over the Span of AD, Roles of Astrocytes and Microglia Change
Reactive astrocytes spell trouble for synapses, while microglial transform from protective to destructive as disease progresses.
Lysosomal Protein TMEM106b Is Tightly Linked to TDP-43, Tau Pathology
Neurons with TMEM106B aggregates lose nuclear TDP-43 in ALS models. In tauopathy models, they accumulate no p-tau.
Trontinemab Data Strengthen Hope for Brain Shuttles
Trontinemab swooped into the brain and removed amyloid efficiently, while causing few cases of ARIA. One person with cerebrovascular pathology died.
Is ARIA an Inflammatory Reaction to Vascular Amyloid?
Scientists at AAIC said ARIA-E resembles inflammation related to cerebral amyloid angiopathy. The prime suspect? The complement cascade.
Two New Deaths on Leqembi Highlight Need to Better Manage ARIA
These are the first deaths reported from clinical use of lecanemab. One was APOE4 homozygote; both developed severe ARIA-E and seizures.
Leqembi: Side Effects No Worse in Clinical Use Than They Were in Trial
ARIA rates have been the same or lower than in the Phase 3 trial. About 9,000 people are being treated in the U.S., half as many in Japan. EMA reverses course, recommending approval.
Questions, Questions for Donanemab, Lecanemab
As immunotherapies enter care, scientists explore when to stop them, how amyloid removal relates to cognitive benefit, and whether fluid markers will track both plaque and tangles responses.
Fully Loaded: Secondary Prevention Studies of Lecanemab, Donanemab
In Madrid, researchers touted the benefits of plasma prescreening and showed baseline data on these early AD populations. Meanwhile, remternetug has begun Phase 3.
Tau Modification Drugs Take a Hit with Negative Trial
Lilly’s Phase 2 trial of its O-GlcNAcase inhibitor ceperognastat failed to meet clinical endpoints. The drug’s adverse events suggest potential off-target effects.
Finally, Therapeutic Antibodies Start to Reduce Tangles
Bepranemab results bolster hopes for antibodies targeting tau’s middle section. Whether tangle clearance will improve clinical outcomes remains unclear.
Donanemab: Small Tweak in Titration, Big Gain in Safety?
By starting at a low dose and upping it stepwise for four months, scientists nearly halved the risk of ARIA while preserving plaque clearance.
Biomarkers Suggest Black and Hispanic People Less Likely to Have Amyloid
To some, the findings suggest that non-AD pathologies, driven by other comorbidities, might contribute to cognitive decline in these populations.
Some Alzheimer’s Blood Tests Are Racing Toward IVD Certification
Vendors of plasma p-tau217-based tests are filing with U.S. and European regulators for approval of fully automated, in vitro diagnostics.
Current Filters
No filters selected